Glycated Albumin Market - Size, Share, Trends, and
Forecast to 2026
Glycated albumin refers to albumin that are bonded to glucose. Albumin is present in blood
and body fluids organs, and functions to maintain the shape of cell and helps in the
distribution of hormones, nutrients, and some drugs in the body. Glycated albumin has been
described as novel biomarkers for the detection and management of diabetes. It has also gained
importance in glycemic monitoring for diabetes mellitus over the past few decades.
Market Dynamics
Increasing approval of novel glycated albumin products by key players in the market is
expected to drive global glycated albumin kits/assays market growth in the near future. For
instance, in 2017, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to
Japan-based Asahi Kasei Pharma Corporation for its new Lucica Glycated Albumin-L, an in vitro
diagnostic assay kit for glycated albumin (GA-L).
Furthermore, increasing prevalence of diabetes is expected to increase the demand for glycated
albumin products, which can be used for the diagnosis/ detection of different types of diabetes
such as type 1, and type 2 diabetes. For instance, according to the data published by the
American Diabetes Associations in 2015, diabetes is the 7th leading cause of death in the U.S.,
where around 30.3 million people in the U.S. are suffering from diabetes. Among these, around
193,000 people in the U.S. below the age of 20 are suffering from diabetes.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1957
Increasing number of approvals of novel glycated albumin products in the market is expected to
fuel the glycated albumin market growth in the near future
In 2015, Asahi Kasei Pharma Corporation received CE Marking for its new Lucica Glycated
Albumin-L, an in vitro diagnostic assay kit, for glycated albumin (GA-L) in Europe. Lucica
Glycated Albumin-L is used for the quantitative measurement of glycated albumin in human